A resolution expressing the sense of the Senate that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
- Bill Number
- S.Res. 732
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-05-14: Referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S2309-2310)
- Last Updated
- 2026-05-29T16:11:21Z
AI-Generated Summary
Summary of S. Res. 732
Purpose
This resolution expresses the sense of the Senate that more than 25 years of real-world data and peer-reviewed studies confirm the safety and effectiveness of mifepristone for medication abortion. It states that laws and policies on access to this care should remain equitable, transparent, and grounded in the best available scientific evidence rather than political considerations.
Key Provisions
- Affirms the FDA's role under the Federal Food, Drug, and Cosmetic Act to base drug approvals and regulations like Risk Evaluation and Mitigation Strategies (REMS) on scientific evidence of safety and effectiveness.
- Highlights the FDA's 2021 and 2023 reviews that updated mifepristone regulations to allow mail and pharmacy dispensing while maintaining safety standards.
- Notes mifepristone's approval after extensive clinical trials, its use in over 90 countries, and endorsements by organizations such as the World Health Organization, American Medical Association, and American College of Obstetricians and Gynecologists.
- Recognizes that medication abortion accounted for 63 percent of U.S. abortions in 2023 and addresses access barriers following the Supreme Court's Dobbs decision, which ended nationwide protections for abortion.
- Emphasizes that restrictions disproportionately affect certain groups and calls for preserving telemedicine prescribing and mail or pharmacy dispensing.
Significant Changes to Existing Law
This resolution introduces no changes to existing law. As a non-binding Senate resolution, it does not amend statutes or alter FDA regulations but instead outlines the Senate's views on current policies governing mifepristone and medication abortion access.
Potential Impacts
- On government agencies: It may encourage the FDA to continue evidence-based reviews of mifepristone without added restrictions, potentially influencing agency decisions on REMS elements.
- On citizens: It supports maintaining access for patients, which could reduce travel distances, wait times, and barriers for those seeking care, particularly in states with abortion limits.
- On international relations: The resolution references global standards, such as the World Health Organization's inclusion of mifepristone on its essential medicines list, but does not propose new international actions.
Main Stakeholders Affected
- Patients seeking medication abortion, including Black and Indigenous people, people of color, immigrants, those with lower incomes, rural residents, LGBTQ+ individuals, people with disabilities, and those experiencing intimate partner violence.
- Healthcare providers and pharmacies certified to prescribe or dispense mifepristone.
- The FDA and other federal health agencies.
- State governments and policymakers in the 20 states with abortion bans or restrictions as of May 2026.
- Medical and scientific organizations involved in reproductive health.
Notable Legal, Constitutional, or Political Implications
- The resolution references the Supreme Court's Dobbs v. Jackson Women's Health Organization decision (2022), which overturned prior precedents and returned abortion regulation to the states, creating varied access across the country.
- It underscores the FDA's statutory authority to regulate drugs based on science and warns against lawsuits that challenge mifepristone approvals using claims of misinformation.
- Politically, it highlights tensions between federal scientific oversight and state-level restrictions, while stressing equitable access to avoid worsening health disparities for marginalized groups.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (46)
Sen. Baldwin, Tammy [D-WI], Sen. Schumer, Charles E. [D-NY], Sen. Wyden, Ron [D-OR], Sen. Murray, Patty [D-WA], Sen. Smith, Tina [D-MN], Sen. Alsobrooks, Angela D. [D-MD], Sen. Bennet, Michael F. [D-CO], Sen. Blumenthal, Richard [D-CT], Sen. Blunt Rochester, Lisa [D-DE], Sen. Booker, Cory A. [D-NJ], Sen. Cantwell, Maria [D-WA], Sen. Coons, Christopher A. [D-DE], Sen. Cortez Masto, Catherine [D-NV], Sen. Duckworth, Tammy [D-IL], Sen. Durbin, Richard J. [D-IL], Sen. Fetterman, John [D-PA], Sen. Gallego, Ruben [D-AZ], Sen. Gillibrand, Kirsten E. [D-NY], Sen. Hassan, Margaret Wood [D-NH], Sen. Heinrich, Martin [D-NM], Sen. Hickenlooper, John W. [D-CO], Sen. Hirono, Mazie K. [D-HI], Sen. Kaine, Tim [D-VA], Sen. Kelly, Mark [D-AZ], Sen. Kim, Andy [D-NJ], Sen. King, Angus S., Jr. [I-ME], Sen. Klobuchar, Amy [D-MN], Sen. Luján, Ben Ray [D-NM], Sen. Markey, Edward J. [D-MA], Sen. Merkley, Jeff [D-OR], Sen. Murphy, Christopher [D-CT], Sen. Ossoff, Jon [D-GA], Sen. Padilla, Alex [D-CA], Sen. Peters, Gary C. [D-MI], Sen. Reed, Jack [D-RI], Sen. Rosen, Jacky [D-NV], Sen. Sanders, Bernard [I-VT], Sen. Schatz, Brian [D-HI], Sen. Schiff, Adam B. [D-CA], Sen. Slotkin, Elissa [D-MI], Sen. Shaheen, Jeanne [D-NH], Sen. Van Hollen, Chris [D-MD], Sen. Warner, Mark R. [D-VA], Sen. Warnock, Raphael G. [D-GA], Sen. Welch, Peter [D-VT], Sen. Whitehouse, Sheldon [D-RI]
Recent Actions
- 2026-05-14: Referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S2309-2310)
- 2026-05-14: Submitted in Senate
Bill Versions
- Expressing the sense of the Senate that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science. — issued 2026-05-14 — PDF (7 pages)